Studies related to Serum BDNF and Ginkgo biloba

Brain-derived Neurotrophic Factor Levels And Its Val66Met Gene Polymorphism Predict Tardive Dyskinesia Treatment Response To Ginkgo Biloba

Effect Increase
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 157
Sex Both Genders
Age Range 18-29, 30-44, 45-64
Notes for this study:
In persons with schizophrenia and tardive dyskinesia (TD), supplementation of 240mg EGb-761 daily for 12 weeks is able to increase circulating BDNF concentrations and reduce symptoms of TD, but only in Val/Met heterozygotes.